Verily

By Jonah Comstock December 21, 2017
While many of its health-related efforts have been shunted into Verily, Alphabet (the company formerly known as Google) actually made health-related moves across its business this year. From search engine updates to massive research studies to M&A, read on for a timeline of Alphabet subsidiaries’ biggest digital health moves this year. January 26: Verily, Alphabet’s main healthcare subsidiary...
By Dave Muoio November 29, 2017
A slew of digital diabetes care companies have announced integrations with the upcoming virtual Type 2 diabetes management platform being developed by Onduo, a joint venture of Verily and Sanofi. These announced services include Voluntis’ Insulia, a digital insulin dose recommendation and coaching system; Glytec’s Glucommander Outpatient, cloud-based software that evaluates blood glucose and...
By Jonah Comstock November 8, 2017
Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some time assuaging investor fears about that friction. “Late in the third quarter, the FDA approved Abbott's FreeStyle Libre flash glucose monitoring system,” Sayer said on the call. “We always believed the...
By Jonah Comstock October 3, 2017
All of the diverse operations of Verily, the life sciences technology company that began its life as Google X Life Sciences, can be summed up with a simple sentence: We should be treating our bodies at least as well as we treat our cars. At the Health 2.0 Fall Conference in Santa Clara this week, Verily Chief Technology Officer Brian Otis spoke with Health 2.0 cofounder and CEO Dr. Indu Subaya on...
By Jonah Comstock September 26, 2017
Just two months after announcing the applications for its pre-certification program pilot, the FDA has announced the nine companies that will be participating. The list includes major tech companies Apple and Samsung; health tech companies Verily, Pear Therapeutics, Tidepool, and Phosphorus; pharmaceutical companies Roche and Johnson & Johnson; and Fitbit — an interesting inclusion insofaras...
By Jonah Comstock August 7, 2017
The University of North Carolina is tapping Google's Verily Life Sciences and MindStrong (the company for which Dr. Thomas Insell recently left Verily) for an ambitious 19-site study of post-traumatic stress disorder. The study, called the Aurora Study, is funded by a $21 million NIH grant and aims to enroll 5,000 people. Aurora was launched last September and has sought private funding to...
By Jonah Comstock August 3, 2017
DexCom hasn’t been shy about its plan for opening up the CGM market by encouraging CGM use in a wider group of people with diabetes — including, eventually, people with Type 2 diabetes. On its second quarter earnings call, the company went deep on that focus on the future. “More and more people with diabetes are adopting CGM that as the primary tool to manage their condition, especially as we...
By Jonah Comstock June 19, 2017
Mindstrong Health, the mental health startup that former NIMH director Dr. Thomas Insel left Verily for last month, has raised $14 million. Foresite Capital and ARCH Venture Partners led the round, with additional participation from Optum Ventures, Berggruen Holdings, and the One Mind Brain Health Impact Fund.  Although it has been reported that Insel left Verily to start Mindstrong, the startup...
By Heather Mack May 19, 2017
The days of claiming artificial intelligence as a feature that set one startup or company apart from the others are over. These days, one would be hard-pressed to find any technology company attracting venture funding or partnerships that doesn’t posit to use some form of machine learning. But for companies trying to innovate in healthcare using artificial intelligence, the stakes are...
By Jonah Comstock May 18, 2017
As Scott Gottlieb kicks off his tenure as FDA commissioner, former commissioner Robert Califf has a new gig as well. Califf revealed in a blog post that he has taken a job at Verily, the life sciences arm of Alphabet, as well as returning to professorial positions at Duke and Stanford. Although the details of his role are still unclear, Califf will work on Verily’s Baseline study, an effort to...

Editor's Pick

link steroid-pharm.com

also read